Material Insights · Understanding the Material World

Recombinant DNA (genetic engineering): Overview

What it does

The job the technology does for people, in a short paragraph

Recombinant DNA lets scientists move a gene from one organism into another, so that a host such as a bacterium or a cultured cell makes a protein it would not make on its own. The first experiments succeeded in 1973, and the first product, human insulin, was approved in 1982 [1]. The method now underlies many biological medicines and genetically modified crops [1].

as of 2026-11-11

How it works

The working principle in plain words, step by step

Every living thing stores its instructions in DNA, written in the same four-letter code. That shared code is what makes the method possible: a human gene placed in a bacterium is read by the bacterium's own machinery. Special enzymes, first found in bacteria, cut DNA at particular places, and the cut pieces from different sources can be joined [1][3]. The joined DNA is carried into a host cell, which copies it each time it divides [1]. The cells read the gene and make its protein. For a medicine, the protein is then purified in licensed plants and each product is approved by regulators before use.

as of 2026-11-11

Key figures

The handful of numbers that size it up, each with its unit, year and source

FigureValueUnitYearSource
People with type 2 diabetes who rely on insulin, more than60million people2021[5]
People with type 1 diabetes for whom insulin makes the disease manageable9million people2021[5]
Share of the insulin market held by three multinational companies, more than90%2021[5]
Possible saving from biosimilar insulins, more than25%2021[5]

as of 2026-11-11. Insulin, the first recombinant medicine, is used as the clearest measure of reach; no world figure for all recombinant products was found.

Where it is used

The main places and products the technology is found in

  • Medicines such as human insulin, growth hormone and many vaccines and antibodies
  • Enzymes for food, detergents and industry
  • Genetically modified crops
  • Basic research in biology and medicine
  • Gene therapy and gene editing research

as of 2026-11-11

Scale today

How much of it there is now: units in use, made each year and who uses it

Users
More than 60 million people with type 2 diabetes and about 9 million with type 1 depend on insulin [5]
Unit
people
Year
2021
Note
Counts insulin users only, as a guide; no world count of all recombinant products was found.

as of 2026-11-11

Sources

  1. Herbert W. Boyer and Stanley N. Cohen Science History Institute
  2. The Nobel Prize in Physiology or Medicine 1978: summary Nobel Prize Outreach (nobelprize.org)
  3. New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021